companydata.dkORIFARM GENERICS A/S
CVR: 25674030
Secondary names: COPYFARM A/S, PILUM PHARMA A/S, Alternova A/S
The financial health of ORIFARM GENERICS A/S appears stable, with a consistent upward trend in revenue, growing from 688 million DKK in 2020 to 2.34 billion DKK in 2024. Profitability has fluctuated, peaking at 150 million DKK in 2021 but stabilizing around 60 million DKK in recent years. Equity has shown significant growth, increasing from 201 million DKK in 2020 to 554 million DKK in 2024, indicating a strong capital position. However, the decline in profit margins from 2021 suggests potential concerns regarding cost management or competitive pressures in the medical supplies industry. Overall, ORIFARM GENERICS A/S is positioned as a significant player in the wholesale trade of medical and hospital supplies, with a solid revenue base and improving equity.
AI-generated summary
Overview
Details
Contact
Advertising protectedPurpose
Selskabets formål er at foretage salg af fortrinsvis generiske lægemidler i Danmark.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 2.3 mia. | 59.9 mio. | 1 mia. | 554.5 mio. | 289 | |
History
Ownership
Management
Directors
Board
Founders
Production units (3)
Similar companies
Companies in the same industry and area